UNSPSC 51352307: Pentafluranol

This classification denotes a non-steroidal estrogen with the molecular formula C17H15F5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95RFZ48151, chemically known as 4,4-((1r,2s)-1-methyl-2-(2,2,2-trifluoroethyl)ethylene)bis(2-fluorophenol) but generally known as pentafluranol, which bears US NIH Compound Identifier 3047826. European Medicines Agency schedules Pentafluranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09677MIG.

UNSPSC 51352307 Pentafluranol is a Commodity code representing specialized pharmaceutical active pharmaceutical ingredients and chemical compounds procured by state and local health systems, cooperative purchasing alliances, and government pharmacy programs. State and local governments source pentafluranol and related pharmaceutical compounds primarily through multistate cooperative purchasing vehicles that aggregate demand across participating state agencies, counties, and healthcare facilities to achieve volume discounts and standardized supply agreements. The scope of work under this code involves manufacturers supplying FDA-compliant pharmaceutical products with certified Good Manufacturing Practices (cGMP) compliance and Drug Supply Chain Security Act (DSCSA) certification, maintaining contractual relationships with authorized pharmaceutical wholesalers, and delivering products with minimum six-month shelf life and expiration dates at least one year from manufacture. Purchasing entities require vendors to provide detailed product specifications including National Drug Codes (NDC), stock keeping units (SKUs), universal product codes (UPCs), dosage forms, strengths, and manufacturing locations, along with flexible pricing structures supporting flat pricing, net price formats, and WAC-minus discounting models.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a representative solicitation on January 20, 2026, seeking manufacturers for generic multi-source pharmaceuticals and OTC products to supply participating state and local government facilities in Minnesota and Oregon (RFP S1070000015802, due March 26, 2026). MMCAP requires manufacturers to maintain relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and to implement chargeback systems and electronic data interchange (EDI) capability. Award evaluations emphasize price competitiveness (75 percent), with secondary weight on fixed pricing structures (10 percent), administrative fee compliance (5 percent), EDI capability (5 percent), and administrative format requirements (5 percent). Awarded vendors will commence supply to wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026, on a two-year contract term with optional extensions at MMCAP's discretion through June 30, 2028.